Interagency Patent Coordination and Improvement Act of 2025

1. 01

   How might improved coordination between the Patent Office and FDA affect the timeline for pharmaceutical companies to bring new drugs to market?

2. 02

   What specific information would be shared between these agencies, and what safeguards should protect proprietary pharmaceutical data?

3. 03

   Which stakeholders—patent examiners, FDA staff, or drug developers—would bear the costs of implementing these new interagency processes?

Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.